Tarsons Products Limited

Tarsons Products Limited

308.65
INR
+8.65
(+2.88%)
2.08EPS
128.62P/E
14.26BMarket Cap
Nov 06Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
34.88
34.3
44.74
57.83
52.88
55.39
73.41
79.05
82.89
Basic EPS, GAAP
7.65
7.94
13.52
19.46
15.17
8.01
5.59
2.69
2.08
Free Cash Flow per Basic Share
3.42
7.49
0.75
-9.37
-21.49
-15.34
-7.04
-1.33
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
25.42
37.13
45.92
92.06
107
115.19
118.45
119.29
- -
Tangible Book Value per Share
25.42
37.13
45.81
91.94
106.9
102.19
106.37
108.06
- -
Basic Weighted Avg Shares
51
51
51
52
53
53
53
53
53
Sales/Revenue/Turnover
1,777
1,750
2,279
2,992
2,814
2,947
3,906
4,206
4,414
Operating Margin (%)
34.62
32.66
40.53
44.84
37.14
21.44
13.64
7.56
3.53
Depreciation Expense
146
142
137
220
285
404
625
965
1,036
Net Income, GAAP
390
405
689
1,007
807
426
298
143
111
Effective Tax Rate (%)
30.21
23.72
25.49
25.43
25.76
29.83
33.55
34.6
36.76
Profit Margin (%)
21.93
23.16
30.22
33.65
28.69
14.47
7.62
3.4
2.51
Working Capital
431
794
710
2,096
1,891
221
668
16
- -
LT Debt
187
59
33
94
807
1,118
2,123
2,160
- -
Total Equity
1,353
1,976
2,443
4,898
5,693
6,129
6,302
6,347
- -
Return on Invested Capital (%)
- -
20.14
26.98
25.38
13.02
5.65
3.84
2.01
- -
Return on Capital (%)
- -
20.74
27.73
26.26
14.09
6.36
4.6
2.9
- -
Return on Common Equity (%)
- -
24.35
31.17
27.42
15.24
7.21
4.79
2.26
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,769
- -
LT Borrowings
- -
2,095
- -
LT Finance Leases
- -
65
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
53
53
Market Capitalization
12,413
8,857
14,259

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,658
- -
Cash, Cash Equivalents & STI
- -
253
- -
Accounts Receivable, Net
- -
854
- -
Inventories
- -
1,298
- -
Total Current Liabilities
- -
2,642
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,769
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.58%
0.71%
Free Cash Flow
- -
-278.67%
-81.04%
Net Income, GAAP
- -
-20.58%
-51.89%
Sales/Revenue/Turnover
- -
14.06%
7.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
848
992
957
1,127
3,906
2026
914
1,023
1,079
1,209
4,206
2027
1,102
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.75
1.93
0.99
1.92
5.59
2026
0.34
0.62
0.95
0.79
2.69
2027
-0.27
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Sanjive Sehgal
Full Time Employees
1,108
Sector
Process industries
Industry
Containers/Packaging
Address
Martin Burn Business Park Kolkata WB India 700091
IPO Date
Nov 26, 2021
Business
Tarsons Products Limited is a leading manufacturer and supplier of advanced plastic laboratory products primarily serving the life sciences industry. The company produces a comprehensive range of core products including disposable plastic labware, centrifuge ware, cryo labware, tissue culture ware, liquid handling systems such as pipette tips and microtips, biohazard and safetyware, clinical and microbiology labware, and related laboratory instruments. Tarsons operates a diversified portfolio spanning over 1,700 SKUs across approximately 300 product categories designed for use in molecular biology, cell culture, genomics, proteomics, immunology, and biopharmaceutical research environments. Founded over four decades ago and headquartered in Kolkata, India, Tarsons distributes its products extensively across India and internationally. In a major strategic expansion during the last two years, Tarsons completed the acquisition of the Hamburg-based Nerbe group, including Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG, through its wholly owned subsidiary Tarsons Life Science Pte Ltd, effective January 1, 2024. This acquisition significantly enhances Tarsons’ international market penetration, especially in Europe, and expands its product line to include specialized plastic consumables for life science laboratories. The company is also developing infrastructure by acquiring 6 acres of land at Amta to establish a fulfillment center, radiation facility, and to scale manufacturing capabilities. Tarsons aims to leverage this expanded operational capacity and international footprint to increase exports to approximately 120 countries over the coming decade, underscoring its strategic shift towards global growth. It remains backed by ADV Partners, a global private equity firm. Tarsons Products Limited remains focused on innovation and research and development to customize labware to precise scientific needs, maintaining a strong pan-India distribution network supported by a dedicated sales force. The company continues to emphasize quality, creativity, and service in delivering laboratory solutions geared to improve the accuracy and efficiency of scientific exploration and research. Its broad geographies of operation now include India, Europe, and markets targeted for expansion globally, positioning it as a pivotal supplier within the labware and life sciences consumables segment.